BCRX BioCryst Pharmaceuticals Inc.

BioCryst to Present at 44th Annual J.P. Morgan Healthcare Conference

BioCryst to Present at 44th Annual J.P. Morgan Healthcare Conference

RESEARCH TRIANGLE PARK, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: BCRX) today announced that the company plans to present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 12, 2026, at 1:30 p.m. ET.

A link to the live audio webcast and replay of the presentation may be accessed in the Investors & Media section of BioCryst’s website at .

About BioCryst Pharmaceuticals

BioCryst is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (“HAE”) and other rare diseases, driven by its deep commitment to improving the lives of people living with these conditions. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of potential first-in-class or best-in-class oral small-molecule and injectable protein therapeutics for a range of rare diseases. For more information, please visit or follow us on .

BCRXW

Contact:

Investors:

Media:



EN
06/01/2026

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BioCryst Pharmaceuticals Inc.

 PRESS RELEASE

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4...

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) RESEARCH TRIANGLE PARK, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted one newly-hired employee restricted stock units (RSUs) covering an aggregate of 18,300 shares of BioCryst common stock. The RSUs were granted as of January 2, 2026, as inducements material to such employee entering into employment with BioCryst. The RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs vest in four equal annual ...

 PRESS RELEASE

BioCryst to Present at 44th Annual J.P. Morgan Healthcare Conference

BioCryst to Present at 44th Annual J.P. Morgan Healthcare Conference RESEARCH TRIANGLE PARK, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: BCRX) today announced that the company plans to present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 12, 2026, at 1:30 p.m. ET. A link to the live audio webcast and replay of the presentation may be accessed in the Investors & Media section of BioCryst’s website at . About BioCryst Pharmaceuticals BioCryst is a global biotechnology company focused on developing and commercializing medicines for heredita...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch